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We report an 82-year-old lady who developed sudden onset nodular and erythematous lesions and neutrophilia following an
episode of urinary tract infection. Skin biopsy confirmed the diagnosis of Sweet syndrome. Response to the use of prednisolone
alone was not satisfactory. The skin lesions however showed a sustained response to the regular use of intravenous immunoglobulin
(IVIG) and prednisolone was slowly weaned oﬀ. Our case highlights the possible therapeutic role of IVIG in managing this
condition.
1. Introduction
Sweet syndrome, also termed acute febrile neutrophilic
dermatosis, is the prototype of neutrophilic dermatoses.
Histologically, Sweet syndrome is characterized by a diﬀuse
infiltrate of mature neutrophils in the dermis without
vasculitis. Eosinophils, lymphocytes, and histiocytes may be
observed in variable numbers and a histiocyte-rich stage in
the evolution of Sweet syndrome has been described. Diﬀer-
ential diagnoses include infection, pyoderma gangrenosum,
other neutrophilic dermatoses and vasculitides. The use of
systemic corticosteroids is the mainstay in the management
of Sweet syndrome. Alternative agents, for instance, dapsone
and colchicines, are used in cases of relapse or refractoriness
to corticosteroids.
We describe the clinical course of an 82-year-old lady
with myelodysplasia who developed rapidly progressive
neutrophilia and pustulovesicular skin lesions following an
episode of febrile illness. Skin biopsy confirmed the diagnosis
of Sweet syndrome. The response to systemic corticosteroids
was modest with relapse during treatment. The skin lesions
and neutrophilia showed a prompt and durable response
to the regular use of intravenous immunoglobulin. This
provides evidence to the possible therapeutic role of IVIG in
Sweet syndrome in addition to the use of corticosteroids and
other anti-inflammatory agents.
2. Case Report
An 82-year-old lady with 10-year history of diabetes mellitus,
hypertension, and sick sinus syndrome presented in February
2008 with anaemia and thrombocytopenia. Bone marrow
aspiration and biopsy confirmed myelodysplastic syndrome
(myelodysplastic/myeloproliferative neoplasm, unclassifiable
under the WHO criteria 2008) with normal cytogenetics. She
was treated conservatively with regular blood transfusion.
In November 2008, she developed fever, confusion, and
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marked renal impairment with a creatinine of 350 μmol/L.
Her white cell count (WCC) was 57.47 × 109/L (Neutrophils:
43.18×109/L, Lymphocytes 1.58 × 109/L, Monocytes 1.67 ×
109/L, Eosinophil 0.28 × 109/L, Basophils 1.07 × 109/L).
Frequent myeloid precursors and band forms were present.
There were no circulating blasts. Urine culture grew E. coli
and Klebsiella species sensitive to standard antimicrobials.
Blood cultures at presentation were negative for bacteria
or fungi. In light of her immunocompromised state and
clinical sepsis, she was treated empirically with meropenem.
Despite treatment with meropenem, her neutrophil counts
continued to rise and her fever only showed a modest
response. Repeated sepsis workup including urine and blood
cultures was negative for any microorganisms. On the
next day of admission, pustulovesicular eruptions developed
over her arms and purpuric patches over the left thigh,
shin, and dorsum of her left foot (Figure 1(a)). A skin
biopsy of a suppurative lesion on her left thigh showed
a diﬀuse neutrophilic infiltrate within the mid to upper
dermis, associated with early leukocytoclasis and absence
of vasculitic changes (Figures 1(c) and 1(d)). There was
no evidence of leukaemic infiltration and microbiological
investigations showed no infective organisms. The diagnosis
of Sweet syndrome (acute febrile neutrophilic dermatosis)
was made. Her skin condition deteriorated with exudation
and new lesions over the skin biopsy site. In addition,
there was evidence of epidermal necrosis over the left ankle.
Bone marrow examination did not show any evidence of
leukaemic transformation.
Given her immunocompromised state secondary
to MDS, she was given a single dose of intravenous
immunoglobulin (IVIG) at 21 grams (0.5 g/kg) 5 days after
admission with the intention of promoting recovery from
infection and due to the possibility of viral infections in
light of fever and rash. Intriguingly, both the fever and
the neutrophilia responded promptly (Figure 2). Thereafter
prednisolone (30 mg daily) was started as standard treatment
for Sweet syndrome. In view of the initial response to IVIG,
another dose of 21 grams was given 5 days after the initial
dose. The pustulovesicular lesions and her renal function
also showed progressive improvement.
Her white cell count gradually dropped to 10.4 × 109/L
(absolute neutrophil count 9.2 × 109/L) 3 weeks after her
admission. Prednisolone was gradually tailed down within
three weeks to 5 mg daily. However, her skin condition
deteriorated with worsening ulceration over the left thigh
and new nodular lesions on the left arm and leg. At the
same time, her neutrophil count also increased. Prednisolone
was stepped up to 40 mg per day. In addition to that,
two consecutive doses of IVIG were given. Colchicine was
added but was discontinued after four days due to diarrhea.
Her skin condition was stabilized but the neutrophil count
continued to rise. IVIG was administered at the same dose
for two consecutive days a week later. Dapsone was added
on day 55 of her admission and was given for 10 days.
The neutrophil count dropped thereafter. Her renal function
normalized 2 months after initial presentation. Monthly
dose of IVIG was administered and prednisolone could be
slowly tailed oﬀ without worsening of her skin condition at
(a) (b)
(c)
(d)
Figure 1: Clinicopathologic features of Sweet syndrome in our
patient at diagnosis: (a) Photograph showing the purpuric patches
and pustulovesicular lesions over the left leg and dorsum of foot
at diagnosis. (b) Photograph showing the resolving skin lesions
over the left leg and dorsum of foot at the time of writing the
manuscript. (c) Low power H & E of skin showing diﬀuse infiltrate
of dermis and superficial subcutis with neutrophils (arrow). There
is incipient necrosis of the epidermis. Dimension bar (left lower
corner) 250 microns. (d) High power H & E of skin—the arrow
shows focal leukocytoclasis without vasculitis—dimension bar (left
lower corner) 50 microns.
the time of writing this paper 8 months after presentation
(Figure 1(b)).
3. Discussion
Clinically, Sweet syndrome is characterized by systemic upset
including fever and malaise, and peripheral neutrophilia.
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Figure 2: The eﬀect of various pharmacotherapies on the absolute
neutrophil count and temperature (each arrow represents a 21-
gram-dose of IVIG).
The cutaneous features include painful and nonpruritic
asymmetrical erythematous plaques, papules, and nodules
of around 2 to 3 centimeters mostly aﬀecting the upper
extremities, face, and neck [1, 2]. Pathergy phenomenon has
been described in which skin lesions occurred at biopsy,
venepuncture, and intravenous drip sites. Involvement of
eyes as well as transient renal, liver, pancreatic, neurologic
and psychiatric manifestations has been described but is
unusual [3]. Sweet syndrome has a marked female prepon-
derance and it aﬀects primarily the middle age population [3,
4]. Most cases were associated with underlying malignancy,
notably myelodysplastic syndrome, acute myeloid leukaemia,
and myeloproliferative disorders and less commonly breast
cancer and solid organ tumors of the genitourinary and
gastrointestinal tracts.
The pathogenesis of Sweet syndrome is poorly under-
stood. Immune complex vasculitis, T-cell activation, and
altered neutrophil function have been postulated but
experimental evidence was lacking. More recently, dereg-
ulated secretion of interleukins 1, 3, 6, and 8, gran-
ulocyte colony-stimulating factor (G-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF), and inter-
feron gamma have been reported [5].
The optimal treatment for Sweet Syndrome has not been
defined. Prednisolone is the mainstay of treatment. Rapid
response is often seen but recurrence is frequently seen.
Steroid refractory and/or relapsed diseases are often treated
with nonsteroidal anti-inflammatory drugs, colchicine, dap-
sone, potassium iodide, doxycycline and clofazimine [1, 3],
and more recently etanercept, a tumor necrosis factor alpha
(TNF-α) antagonist [6], based on the hypothesis that TNF-α
activates neutrophils in this disease.
Our patient presented with systemic upset, fever, neu-
trophilia and typical cutaneous, and histological features of
Sweet syndrome. Surprisingly, IVIG resulted in a prompt
and dramatic response in fever and neutrophilia. Such
response was clearly observed before the commencement
of prednisolone. In addition, the skin condition showed
a progressive and sustained improvement with regular
administration of IVIG. The exact mechanism is not known.
However, our observations should be interpreted with cau-
tion since prednisolone, colchicines, and dapsone have also
been used and it was likely that they might have contributed
to the improvement of the patient’s condition. Whether
these agents, when used with IVIG, might provide synergism
to the latter would also have to be carefully examined.
Secondly, the initial response of fever and neutrophilia to
IVIG might be related to its passive immunity in addition to
the use of broad spectrum antibiotics. Notwithstanding this
limitation, our clinical observation might provide us with a
ground for further evaluating the clinical eﬃcacy of IVIG
in the treatment of this disease. Recently, Haliasos et al. [7]
also reported a 4-year-old girl with chronic recurrent Sweet
syndrome associated with primary immunodeficiency and
thrombocytopenia being successfully treated with IVIG and
dapsone. Therefore, our case report provided the first piece
of evidence that IVIG ameliorated the clinical course of Sweet
syndrome independent of the immunodeficiency state.
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